Droxidopa
Droxidopa, Northera (droxidopa) is a small molecule pharmaceutical. Droxidopa was first approved as Northera on 2014-02-18. It is used to treat orthostatic hypotension in the USA. It is known to target muscarinic acetylcholine receptor M1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Northera (generic drugs available since 2021-02-18)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| orthostatic hypotension | — | D007024 | I95.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Orthostatic hypotension | D007024 | — | I95.1 | 2 | 3 | 6 | 4 | 1 | 15 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 5 | 2 | 4 | 1 | 13 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | 1 | — | 2 | — | 4 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | 1 | — | 2 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | 1 | — | 1 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple system atrophy | D019578 | — | — | 2 | 3 | 3 | — | — | 6 |
| Pure autonomic failure | D054970 | — | — | 1 | — | 4 | — | — | 5 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | — | 4 | — | — | 4 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | 2 | 1 | — | — | 2 |
| Orthostatic intolerance | D054971 | — | — | 1 | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | 2 | — | — | — | 2 |
| Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | 1 | 1 | — | — | — | 1 |
| Hereditary sensory and autonomic neuropathies | D009477 | — | — | — | 1 | — | — | — | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | — | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | 1 | — | — | — | 1 |
| Vasovagal syncope | D019462 | — | R55 | — | 1 | — | — | — | 1 |
| Syncope | D013575 | HP_0012668 | G90.01 | — | 1 | — | — | — | 1 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 1 | — | — | — | 1 |
| Menkes kinky hair syndrome | D007706 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Droxidopa |
| INN | droxidopa |
| Description | Droxidopa is a serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension It has a role as a prodrug, a vasoconstrictor agent and an antihypertensive agent. It is a L-tyrosine derivative and a member of catechols. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 23651-95-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103827 |
| ChEBI ID | 31524 |
| PubChem CID | 92974 |
| DrugBank | DB06262 |
| UNII ID | J7A92W69L7 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,021 documents
View more details
Safety
Black-box Warning
Black-box warning for: Droxidopa, Northera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,042 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use